The global hypoparathyroidism market size is expected to be worth USD 787.4 Million in 2025. It can reach a valuation of USD 1,323.4 Million by 2032. The market is anticipated to peak at a CAGR of 7.7% during the forecast period (2025-2032).

The surge in the cases of hypoparathyroidism or hypopara due to anterior neck surgeries, advances in parathyroid hormone (PTH) surgeries, and focus on drug development by pharmaceutical manufacturers can drive the market growth.

However, the high costs of drugs for the treatment of hypoparathyroidism and inaccessibility to medicines in low-income countries can impede the market growth.

Key Market Insights

The hypoparathyroidism market is anticipated to expand owing to accurate assays for the assessment of PTH levels, advances in PTH-based therapies, and the acquisition of companies to enhance the product pipeline.

• By treatment, the adjunctive therapies segment is expected to score 39.7% market share in 2025. This can be attributed to the use of magnesium supplements, phosphate binders, and thiazide diuretics along with primary treatments.
• By route of administration, the parenteral segment is anticipated to attain 45.2% market share in 2025. The segment growth is driven by the use of injections during hypocalcemic crises or when oral routes are insufficient.
• By end user, the specialty clinics segment is anticipated to attain a strong market share in 2025, owing to the establishment of endocrinology clinics. These clinics can manage the levels of calcium, magnesium, and phosphate and monitor complications like nephrocalcinosis.
• By region, the Asia Pacific is projected to capture a significant market share in 2025, owing to increased awareness levels of hypoparathyroidism and expanding endocrine care infrastructure.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/hypoparathyroidism-market

Hypoparathyroidism Market Report Coverage

Market Dynamics

The hypoparathyroidism market growth is driven by the number of clinical trials under development for keeping PTH levels in check. The large number of hypoparathyroidism cases caused by non-surgical etiologies can facilitate the market growth. On March 17, 2025, the Calypso Phase-III trial by AstraZeneca displayed the high potential of eneboparatide (AZP-3601). The trial demonstrated the continuous effectiveness of taking the drug, which restored calcium levels to normal without dependency on calcium supplements. This can bode well for the market and lead to the development of generics in low-income countries with collaborations.

The approval of Yorvipath by Ascendis Pharma and the buyout of biopharmaceutical startups by major companies can drive the market growth. Early approval of drugs can lead to higher funding in research and development of endocrine disorders and help patients in the long run. Fast-track approvals by the European Medicine Agency and the U.S. FDA can widen the clinical space for research.

Market Opportunity: Innovation in Drug Delivery Pipeline

The rise of next-generation drug delivery systems like long-acting PTH analogs and gene therapy treatments can shape the market in the forthcoming years. AI-powered planning and remote calcium monitoring applications that redefine standard management protocols can bode well for the market.

Market Challenge: Product Recall by Regulatory Agencies to be a Hurdle

The recall of NATPARA by the U.S. FDA in 2019 due to the presence of rubber particulates in the drug created hesitation among patients and led to growth hurdles. Manufacturing issues, coupled with injection problems, also added to the problem and left patients in limbo. However, the approval of drugs has given patients hope and revived the growth of the market.

Analyst’s View

• The hypoparathyroidism market growth is driven by the use of PTH treatment and calcium supplements.
• The parenteral segment is predicted to be the primary route of administration of treatment owing to the unresponsiveness of oral therapies.
• Companies are focusing their efforts on gaining approval from regulatory bodies to get the first-mover advantage in nascent markets.

Recent Developments

Ascendis Pharma announced the Phase 3 PaTHway Trial of the long-term treatment with TransCon PTH (palopegteriparatide) on July 14, 2025. The trial in its 26^th week continued to show reliable assessments of the drug and improvements in quality of life.

Competitor Insights

• Shire Plc
• Entera Bio Ltd.
• Amgen Inc.
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Ascendis Pharma A/S
• Roche Holding AG
• Forte Biosciences Inc.
• AbbVie Inc.
• Eli Lilly and Company

Market Segmentation

• By Treatment

• Hormone Replacement Therapy
• Recombinant Parathyroid Hormone (rhPTH)
• Vitamin D Analogues
• Calcium Supplements
• Adjunctive Therapies
• Magnesium Supplements
• Phosphate Binders

• By Route of Administration
• Oral
• Tablets
• Capsules
• Parenteral
• Injections
• By End User
• Hospitals
• Specialty Clinics
• Homecare Settings

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa